Telomir Pharmaceuticals (TELO)

• Market cap: $80.5M
• 1 day: -0.85%
• 5 days: -6.4%
• 1 month: -7.87%
• 3 months: -12.69%
• 6 months: 1.74%
• Year to date: -12.69%
• 1 year: -36.41%
• 5 years: -76.6%
• 10 years: -76.6%
• Sector: Healthcare
• Industry: Biotechnology

About: Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.

Employees: 5